Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 11/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22032101 | 0.89 | CHRM1 (0.53) | CHRM1CHRM2CHRM5ALDH1A1L3MBTL1 | |
| SCHEMBL22032067 | 0.83 | CHRM1 (0.45) | CHRM1TSHRRECQLCHRM2CHRM5 | |
| SCHEMBL22079708 | 0.81 | TSHR (0.42) | CHRM1TSHRRECQLALDH1A1LMNA | |
| SCHEMBL24106282 | 0.80 | CHRM1 (0.44) | CHRM1TSHRRECQLCHRM2CHRM5 | |
| SCHEMBL24106281 | 0.79 | TSHR (0.44) | CHRM1TSHRRECQLCHRM2ALDH1A1 | |
| SCHEMBL22079714 | 0.77 | TSHR (0.45) | CHRM1TSHRRECQLCHRM2ALDH1A1 | |
| SCHEMBL24106453 | 0.75 | MAPK1 (0.37) | CHRM1TSHRALDH1A1L3MBTL1 | |
| SCHEMBL24106454 | 0.74 | MAPK1 (0.39) | CHRM1TSHRALDH1A1L3MBTL1 | |
| SCHEMBL22032096 | 0.73 | TSHR (0.48) | CHRM1TSHRRECQLCHRM2ALDH1A1 | |
| SCHEMBL22032111 | 0.71 | CHRM1 (0.52) | CHRM1CHRM2CHRM5ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11945801-B2 | Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-04-02 | — | — | US | claimed |
| US-20210387969-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2021-12-16 | — | — | US | disclosed |
| WO-2020115505-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387969-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885TSHR 81/4885RECQL 1199/4885 |
| US-11945801-B2 | Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885TSHR 81/4885RECQL 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.